Ocular Metastasis: Why Your Cancer Doctor Wants You to See a Retina Specialist
Cancer That Has Spread to the Eye at a Glance
Ocular metastasis means a deposit of your existing cancer has settled in the eye. It is not a new, second cancer. Nine of every ten of these deposits land in the choroid, the blood-rich layer just behind the retina1.
A retina specialist is being asked to look because the eye needs its own examination and often its own treatment. Deposits in the eye can shrink with radiation aimed at the eye or, in many people, with the systemic cancer treatment they are already receiving2. Sight is often protected when this is picked up and acted on.
Deposits sit deep inside the eye, behind the retina, where they need a dilated exam plus scans and ultrasound to measure. Retina and ocular oncology specialists do this every week and can tell a metastatic deposit from the several other things that look similar.
They also decide, with your oncologist, whether the eye needs treatment of its own. That judgment turns on how much your vision is threatened, whether one or both eyes are involved, which cancer it is, and whether your systemic treatment is likely to reach it2.
This is a prompt appointment rather than an emergency room visit. Aim to be seen within days to a couple of weeks, and say when booking that your oncologist has raised a possible metastasis in the eye.
Go sooner if your vision is dropping quickly or the eye becomes painful. Those changes are uncommon, and they are worth acting on the same day rather than waiting for the scheduled slot.
What Ocular Metastasis Actually Is
The eye has a layer of dense blood supply behind the retina called the choroid, and that is where cancer cells arriving in the bloodstream tend to lodge. The choroid is involved in about 90 of every 100 cases, the iris in about 8, the ciliary body in about 2, and the retina, optic nerve head, vitreous gel or lens capsule in under 41.
A choroidal deposit usually looks like a flat, pale yellow patch with fluid collecting over it. The largest deposit in an eye averaged about 9 mm across and 3 mm thick, and most sat between the macula and the mid-point of the eye3.
People are often surprised by this. Choroidal metastasis is now considered the most common cancer found inside the adult eye, more common than tumors that start in the eye, and 8 of every 100 people who died of cancer were found to have choroidal deposits at autopsy4.
Cases are being seen more often, because people with metastatic cancer are living longer and because scanning has improved5. That is an uncomfortable statistic attached to a genuinely good trend.
The cells in your eye are the same type as your original cancer. Breast cancer in the eye is still breast cancer, and it usually responds to the treatments that work for breast cancer elsewhere. This is why your oncologist stays in charge of the overall plan.
It does mean the cancer has traveled through the bloodstream, which changes staging and often changes treatment. Your oncologist will explain what it means for your specific plan, and the eye finding is one piece of that conversation rather than the whole of it.
Which Cancers Spread to the Eye and Why
Breast cancer accounts for about 37 of every 100 cases and lung cancer for about 27, with kidney and gastrointestinal cancers about 4 each1. Prostate, skin, thyroid and carcinoid tumors make up smaller shares.
The pattern differs by which cancer it is. Breast primaries more often produce deposits in both eyes and in more than one spot, while lung primaries are more often in one eye (about 82 of every 100) and a single spot (about 77 of every 100)4.
Blood flow explains most of it. The choroid receives a very high volume of blood for its size and its vessels branch into a slow, wide bed, so circulating cells have both the opportunity and the time to settle there.
Nothing you did caused this, and no habit, diet or delay in a routine eye test made the eye a target. It is a consequence of how blood moves, not of anything you could have managed differently.
Sometimes the eye is where the story starts. In a series of 1,111 patients, the primary cancer was already known in 742 of them (about 67 of every 100) and unknown in 369 (about 33 of every 100); of those, the primary was later found in 192 and never identified in 1776.
If nobody has found your primary yet, that is a recognized situation with a standard workup, not a failure of your care. In that same series, 5-year survival did not differ significantly between people whose primary was found before, after, or never6.
Symptoms and What You Might Notice
Blurred vision is the presenting complaint in about 70 to 81 of every 100 people, flashes or floaters in about 5 to 12, and pain in about 5 to 144. Some people describe a fixed gray patch, a warping of straight lines, or a shadow in one part of their field of view.
Pain is unusual, which is why a painless change in vision is worth reporting even when it feels minor. Most vision changes in someone with cancer turn out to be something ordinary, such as a cataract or a dry eye, and they are still worth checking.
Between 9 and 11 of every 100 people with choroidal metastasis have no symptoms at all, and the deposit is found on a routine eye examination4. A deposit off to the side of the retina can sit there without touching the part of your vision you actually use.
This is the main reason your oncologist may want a look even though your sight seems fine. Finding a silent deposit early gives more options than finding a large one later.
Which eyes are involved gives your team information. Deposits from breast cancer are more often found in both eyes and in several spots, while lung cancer more often produces a single deposit in one eye4.
Both eyes being involved sounds worse than one, and it does mean more disease to treat. It does not, on its own, tell you what your vision will be like, because that depends far more on where the deposits sit than on how many there are.
How Ocular Metastasis Is Diagnosed
The visit starts with drops that widen your pupils, then a careful look at the back of both eyes with a bright light and a lens. Your specialist is looking for a pale yellow, flat-topped patch with fluid over it.
A yellow color is present in about 86 of every 100 of these tumors and overlying fluid in about 72 of every 100, and both are among the features that point to metastasis1. Expect blurry vision and light sensitivity for a few hours afterwards, so arrange a lift home.
Two painless scans usually follow. Ultrasound uses sound waves through a gel-covered probe on the closed eyelid to measure thickness and density. Optical coherence tomography, or OCT, uses light to build a cross-section image of the retina.
Metastatic deposits appear as an echodense mass on ultrasound in about 80 of every 100 cases and give a lumpy, bumpy choroidal surface on OCT in about 64 of every 100, both of which help separate them from other tumors1.
Sometimes a dye is injected into an arm vein while a camera photographs the retina as the dye passes through. This is one of the standard tests for choroidal metastasis, used alongside ultrasound and OCT5.
The dye can turn your skin and urine yellow or orange for a day, which is expected and harmless. Tell the team beforehand about any allergy or kidney problem so they can choose the right dye or skip the test.
Most of the time, imaging plus your cancer history is enough, and no biopsy is done. A tumor biopsy may be used to confirm that a deposit is metastatic and to help identify where the primary cancer is5, which matters most when no primary has been found.
It is done with a fine needle through the wall of the eye, under local anesthetic, by a specialist who does this routinely. The idea sounds worse than the procedure, and it is only recommended when the answer would change your treatment.
Treatment Options for Ocular Metastasis
This is the first question your two teams will ask. Systemic treatments that target specific cancer changes, and immunotherapy, can shrink choroidal deposits5. In one series, 10 of 13 eyes managed with systemic therapy alone showed a good tumor response, and final vision was not significantly different from eyes given radiation2.
If your current treatment is working elsewhere in your body, watching the eye closely while it does its job is a legitimate plan rather than a delay in care.
When a deposit threatens central vision or is not responding, radiation is the mainstay. External beam radiation therapy is the most widely used treatment for choroidal metastasis5. Doses of 40 to 60 Gy produced tumor regression in about 85 to 93 of every 100 treated eyes, with vision improved or stable in about 56 of every 1004.
It is given over several short outpatient sessions. Ask how many visits are involved, since travel burden is a real part of this decision when you are already attending oncology appointments.
Not every eye needs a course of radiation. Less invasive office treatments, including photodynamic therapy and injections of anti-VEGF medicine into the eye, can help preserve vision while reducing time spent in medical settings5. Anti-VEGF injections mainly dry up the fluid that blurs vision rather than removing the deposit itself.
For someone whose priority is comfortable, useful sight with the fewest hospital trips, these options are worth raising by name.
Observation is a real option, not a refusal to treat. It fits a deposit that is small, off to the side, causing no symptoms, and already responding to systemic treatment.
Choosing between watching, local radiation and systemic therapy alone depends on the visual threat, whether one or both eyes are affected, the cancer type and its mutations, your ability to travel for treatment, and your expected course2. Ask your team to say out loud which of those is driving their recommendation.
What This Means for Your Vision and Your Outlook
Vision often holds up better than people fear. After radiation, vision was improved or stable in about 56 of every 100 treated eyes4, and final vision was similar in eyes managed with systemic therapy alone in one small series2.
Reading vision depends heavily on whether the deposit sits under the macula, the small central zone you read with. Your specialist can tell you from your scans which situation you are in, and that is a more useful answer than any average.
These numbers are hard to look at, so here is how to hold them. In a series of 1,111 patients, 32 of every 100 were alive at 3 years and 24 of every 100 at 5 years, with wide variation by cancer type: 5-year survival was about 92 of every 100 for carcinoid tumors and lowest for pancreatic and kidney primaries1.
Reported mean survival after an eye deposit was about 21 months for breast primaries and about 12 months for lung primaries4. These figures come from people treated across earlier decades, before several current cancer treatments existed, and they describe groups rather than individuals. Your oncologist's estimate for your own situation is the one that counts.
Eye radiation has side effects worth knowing before you agree to it. Reported complications of external beam treatment included cataract in about 7 of every 100 and radiation damage to the retina in about 3 of every 1004.
Both are manageable problems rather than sight-ending ones in most cases, and cataract in particular is routinely fixable with surgery. Your team weighs these against what an untreated deposit would do to the same eye.
Practical adjustments matter more than most people expect. Better task lighting, larger print, and using your stronger eye deliberately for reading all help. If one eye is affected, depth judgment takes a few weeks to recalibrate, so be careful pouring hot drinks and on stairs at first.
Ask about low-vision rehabilitation early rather than as a last resort. It is available alongside cancer treatment and is not a sign that anyone has given up.
When to Call Your Eye Doctor or Cancer Team
Report a new blurred or gray patch, straight lines that begin to bend, a new shadow at the edge of your vision, or a step down in reading. Also report any change in the eye that was previously unaffected.
Most of these turn out to be treatable, and catching them early is what keeps the options open. Call your eye clinic first, and let your oncology team know as well, since eye changes can be a signal about what the cancer is doing elsewhere.
A few symptoms should not wait for the next appointment. Contact your eye service the same day, or use an emergency service if it is closed, for any of these:
- Sudden vision loss, or a curtain or shadow sweeping across your sight
- Severe eye pain, especially with nausea or a red eye
- A sudden shower of new floaters or persistent flashing lights
These usually point to a separate problem such as a detached retina or raised pressure inside the eye, both of which are treatable when handled quickly.
Monitoring every 3 to 6 months during systemic treatment has been recommended, partly because progression in the eye may mirror progression elsewhere in the body2. Visits are usually closer together right after any eye treatment.
Keep these appointments even during a stretch when you feel well. The eye is one of the few places your team can watch a deposit directly, which makes your scans useful to the whole plan.
Common Questions About Cancer That Spreads to the Eye
It means the cancer has spread through the bloodstream, which is significant, but it does not tell you how much disease is elsewhere. Your staging scans answer that. The eye is a common site because the choroid has such a rich blood supply, and it is the most frequent ocular site for metastasis5. Ask your oncologist what the eye finding changes about your treatment plan specifically, because for many people the systemic plan continues.
Often not, and treatment is aimed squarely at preventing that. After radiation to the eye, vision was improved or stable in about 56 of every 100 treated eyes4. Whether your reading vision is at risk depends mostly on whether the deposit sits under the central retina. Your specialist can tell you that from your scans, and it is a fair question to ask directly at the first visit.
Not always. Systemic therapy and immunotherapy can shrink choroidal deposits5, and in one small series 10 of 13 eyes managed with systemic treatment alone responded well, with final vision similar to eyes given radiation2. The usual approach is to watch the eye closely while your systemic treatment works, and add local treatment if the deposit grows or threatens central vision.
Because it often causes nothing to notice. Between 9 and 11 of every 100 people with a choroidal deposit have no symptoms at all and are found on a routine examination4. A deposit away from the centre of the retina can be sizeable and still leave your vision feeling normal. This is not a missed diagnosis so much as the natural history of where these deposits sit.
Removing a choroidal deposit surgically is not standard practice. Treatment works by shrinking it instead, using radiation, systemic cancer treatment, or office-based options. Removing the eye is reserved for an eye that is blind and painful4, which is an uncommon endpoint. If someone offers you eye surgery for this, it is reasonable to ask for a second opinion from an ocular oncology service.
It is a recognized situation rather than a bad omen. In a series of 1,111 patients, the primary was unknown at the time of the eye diagnosis in about 33 of every 100, and it was never identified in 177 of them6. Five-year survival in that series did not differ significantly between people whose primary was found before, after, or never6. Your team will still search, because finding it can open up targeted treatment.
More Questions About Appointments, Work, and Next Steps
More often at first, then settling into a rhythm alongside your oncology visits. Monitoring every 3 to 6 months during systemic treatment has been recommended, because eye progression may mirror progression elsewhere2. After eye radiation, expect closer checks for the first months. Ask whether your eye appointments can be scheduled on the same days as your oncology visits, since most centers will try to combine them.
Many people can, especially when only one eye is affected and the other sees well. Check the vision standard for driving where you live and be honest with yourself about night driving and depth judgment. At work, better lighting, larger text and reduced glare help. If your job depends on fine central vision, say so at your eye appointment, because it changes how quickly treatment is discussed.
No, and the distinction matters. Ocular melanoma starts in the eye, whereas a metastasis started elsewhere and traveled there. They also look different on scans, with metastatic deposits typically flatter and echodense on ultrasound in about 80 of every 100 cases1. The treatments and the meaning for the rest of your body differ, which is exactly why an ocular oncology opinion is worth having.
Bring back four things: whether a deposit was confirmed, where it sits relative to your central vision, whether the eye team recommends local treatment or watching, and the date of your next eye review. The two teams are expected to coordinate, since ocular progression may reflect systemic progression2. Ask for the eye report to be sent directly to your oncologist rather than relying on your own summary.
- Is the deposit under the central part of my retina, or off to the side?
- Can my current cancer treatment be expected to reach it?
- If we watch it, what change would make you treat the eye?
- How many radiation visits would be involved, and where?
- What are the risks of eye radiation for my other eye conditions?
- Is the other eye affected, and how will you monitor it?
- Who is coordinating between the eye team and my oncology team?
- What symptoms mean I should call you the same day?
- Eye (London), review of large ocular oncology cohorts (2023). Metastatic tumours to the eye. Review of metastasis to the iris, ciliary body, choroid, retina, optic disc, vitreous, and/or lens capsule.
- Frontiers in Oncology, retrospective single-center series of 26 patients (2024). Management of choroidal/ciliary body metastasis in the era of targeted cancer therapy.
- Ophthalmology, retrospective cohort of 420 consecutive patients over 20 years (1997). Survey of 520 eyes with uveal metastases.
- Indian Journal of Ophthalmology, peer-reviewed review (2015). Choroidal metastases: origin, features, and therapy.
- Progress in Retinal and Eye Research, peer-reviewed review (2019). New concepts in the diagnosis and management of choroidal metastases.
- Saudi Journal of Ophthalmology, retrospective cohort of 1,111 consecutive patients at one ocular oncology service (2019). Uveal metastasis in 1111 patients: Interval to metastasis and overall survival based on timing of primary cancer diagnosis.